Annovis Bio, Inc. - ANVS STOCK NEWS

Annovis Bio, Inc. (NYSE: ANVS) has appointed Henry Hagopian III as Chief Financial Officer, succeeding Jeff McGroarty, who is departing to pursue other interests. Hagopian brings over 30 years of finance experience, including significant tenure at Organogenesis. This leadership change comes as Annovis progresses to Phase 3 clinical trials for its drug buntanetap, aimed at treating neurodegenerative diseases. CEO Maria L. Maccecchini expressed confidence in Hagopian's ability to enhance the company's financial strategies as it advances in this critical phase.

Annovis Bio (NYSE: ANVS) has initiated a Phase 3 clinical trial for buntanetap, aimed at treating early Parkinson's Disease (PD). The trial will involve 450 patients over six months, assessing efficacy, safety, and tolerability with primary endpoints including MDS-UPDRS scores. Previous Phase 2a results indicated significant improvements in motor function without major adverse events. The CEO expressed optimism about the potential of buntanetap to enhance patient quality of life. This study seeks to confirm earlier promising outcomes and advance towards regulatory approval.

Annovis Bio, a clinical-stage company targeting neurodegenerative diseases, reported its Q2 2022 financial results. The FDA approved the Phase 3 clinical trial design for its drug, buntanetap, in early Parkinson's patients. The company also submitted an international patent for treating neurological injuries from infections and announced a collaboration with the National Institute on Aging to develop biomarkers. Financially, it holds $36 million in cash, with Q2 expenses totaling $8.7 million in net losses compared to $2.5 million a year prior.

Annovis Bio, Inc. (NYSE: ANVS) announced that CEO Maria Maccecchini will participate in a panel on the Systems Biology of Alzheimer's Disease at the Alzheimer's Association International Conference on August 4, 2022. The panel aims to discuss advanced therapeutic approaches for Alzheimer's and features notable experts including Jeffrey Cummings and Krista Lanctôt. The company’s drug, Buntanetap, has shown promise in improving cognition in Alzheimer's patients and motor function in Parkinson's patients during Phase 2 clinical trials. For more info, visit www.annovisbio.com.

Annovis Bio, Inc. (NYSE: ANVS) announced that its Founder, President, and CEO, Maria Maccecchini, Ph.D., will participate in the Systems Biology of Alzheimer's Disease Panel at the Alzheimer's Association International Conference on August 4, 2022. The panel, moderated by Jeffrey Cummings, MD, and Krista Lanctôt, Ph.D., will discuss innovative therapeutic approaches for Alzheimer's disease. Buntanetap, Annovis's lead compound, has shown promise in clinical trials, improving cognition in Alzheimer's and motor function in Parkinson's patients.

Annovis Bio, Inc. (NYSE: ANVS) announced that the FDA has approved its Phase 3 clinical study of buntanetap for early Parkinson's disease. Following a successful Type B meeting earlier this year, the FDA accepted the final protocol and clinical development plan, allowing longer duration studies. The study will involve 100 sites in the US and EU, with expected recruitment later this summer. Previous Phase 2 trials indicated statistically significant improvements in motor function for PD and cognitive function for AD patients. This progress positions Annovis favorably in the neurodegenerative treatment landscape.

Annovis Bio has submitted an international patent application for Buntanetap, its lead compound, to treat neurological injuries caused by infections. This patent aims to expand its existing intellectual property portfolio, which already covers various neurodegenerative diseases like Alzheimer's and Parkinson's. If granted, the patent could protect the company’s innovations until 2042. Data indicates Buntanetap decreases neurotoxic protein levels and shows promise in clinical trials, enhancing cognitive and motor functions in patients.

Lantern Pharma (NASDAQ: LTRN) announced Dr. Maria L. Maccecchini as a nominee for its Board of Directors during the Annual Meeting on June 8, 2022. Dr. Maccecchini, a seasoned biopharmaceutical executive, brings decades of experience, particularly in neurodegenerative diseases. Concurrently, Leslie W. Kreis, Jr. will not seek reelection. Lantern's President, Panna Sharma, emphasized Dr. Maccecchini's potential contributions to ongoing clinical trials. Lantern is focused on utilizing its RADR^® platform to enhance oncology drug development.

Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage company focused on neurodegenerative diseases, will have CEO Maria L. Maccecchini present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on demand for attendees. Annovis is developing treatments targeting Alzheimer's and Parkinson's diseases, with ongoing Phase 2 studies assessing their drug's efficacy in improving memory loss and brain function. For more details, visit www.annovisbio.com.